GlassScriptPhysician profile
James Mathew Halverson
NPI 1902899016
$12,104.39
in general payments reported to CMS, 2019-2025
53 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $1,339 · 2021: $1,875 · 2022: $1,557 · 2023: $1,554 · 2024: $1,785 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,043.77 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,955.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,218.89 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $1,120.51 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $1,028.68 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,025.82 | 2021-2025 | |
| Pfizer INC. | $915.75 | 2019-2025 | |
| Lilly USA, LLC | $773.38 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.45 | 2019-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $278.35 | 2021 | |
| Abbott Laboratories | $272.49 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.60 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $209.38 | 2019-2021 | |
| Insightec,INC | $184.05 | 2024 | Exablate |
| Mylan Specialty L.P. | $162.85 | 2020-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $156.72 | 2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $151.57 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $131.62 | 2019-2023 | |
| Boston Scientific Corporation | $112.95 | 2019-2025 | Watchman Flx, Watchman Access System |
| Sanofi Pasteur INC. | $105.25 | 2019-2025 | |
| Antares Pharma, INC. | $95.09 | 2022-2025 | Xyosted |
| Organon LLC | $94.79 | 2021-2022 | |
| Bausch Health US, LLC | $93.28 | 2019-2021 | |
| Exact Sciences Corporation | $92.78 | 2023-2025 | Cologuard Collection Kit |
| Optinose US, INC. | $89.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.05 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.05 | 2019-2021 | |
| Allergan, INC. | $78.56 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $72.73 | 2019-2020 | |
| Irhythm Technologies, INC. | $67.86 | 2023 | Zio Xt Patch |
| Collegium Pharmaceutical, INC. | $64.03 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.38 | 2021-2023 | |
| Dexcom, INC. | $61.51 | 2023-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $59.86 | 2022-2023 | Quviviq |
| Lundbeck LLC | $53.34 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $49.91 | 2024-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $49.50 | 2019-2025 | Capvaxive, Gardasil 9 |
| Gilead Sciences, INC. | $49.12 | 2019-2020 | |
| Shire North American Group INC | $43.39 | 2019 | |
| Amarin Pharma, INC. | $43.10 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.94 | 2019-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $37.54 | 2023 | Sunosi |
| Xeris Pharmaceuticals, INC. | $33.96 | 2025 | Keveyis |
| Bardy Diagnostics, INC. | $29.36 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.17 | 2023-2025 | Zoryve, Seglentis |
| Endo USA, INC. | $24.19 | 2025 | Xiaflex, Aveed |
| Otsuka America Pharmaceutical, INC. | $20.79 | 2021 | |
| Eisai INC. | $20.53 | 2021 | |
| Ucb, INC. | $20.42 | 2025 | Rystiggo |
| Corium, LLC | $18.79 | 2023 | Adlarity |
| Hologic Sales and Service, LLC | $18.23 | 2024 | Thinprep 2000 Processor, Aptima |
| Resmed Corp | $14.46 | 2019 | |
| Kaleo, INC. | $13.27 | 2019 | |
| Genentech USA, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Halverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.